Dodaten kriterium koj ne e povrzan sokvalitetot, a se odnesuva na regulatorni baranja e t.n. regulatorenprioritet. Dokolku e potrebna proverka na isporachatelot sporedovoj kriterium, togash za istiot proverka se planira vo prvatagodina od trigodishniot plan nezavisno kakov status ima od rizikanalizata. Rizik analizata i planot za proverka se azhuriraatredovno, sledejkji go kvalitetot na materijalot (preku softverotAlkaSAP) ili uslugata koja isporachatelite ja dobavuvaat, nivniotregulatoren status (sertifikati od regulatorni agentsii) isekojdnevnata komunikatsija. Ova znachi deka nisko rizichenisporachatel mozhe za kratko vreme da stane sredno ili visokorizichen i negovata proverka da dobie prioritet i obratno.Proverkite gi izvrshuvaat obucheni i iskusni litsa od Alkaloid AD.Za proverka na isporachatelite mozhe da se angazhira i nekojanezavisna agentsija za proverka od treta strana.REZULTATIVo tekot na 2009, 2010 i prvite tri mesetsi od 2011 godina iz vr she -na e proverka na 15 proizvoditeli na aktivni farmatsevtski in -gre dienti od koi kaj 12 proverkite se izvrsheni od strana naobucheni litsa od Alkaloid AD, a kaj 3 proverkata e izvrshena odtreta strana. Vo proverkite opfateni se vkupno 26 aktivni far ma -tsev ts ki ingredienti. Vo pochetokot na 2011 napravena e proverkana eden proizvoditel na ekstsipienti. Izvrshena e i proverka naedna dogovorna laboratorija i dve dogovorni proizvodstva. Votekot na navedeniot period provereni se dva proizvoditela naprimarni pakovni materijali i chetiri isporachateli na sekundarnaambalazha. Najchesta prichina za nenavremeno ispolnuvanje na planotza proverka e prezafatenosta na isporachatelite (osobeno naaktivni farmatsevtski ingredienti) so proverki od site svoi ku pu -va chi, pa nekogash proverkata iako planirana vo konkreten termin seza ka zhuva za prviot mozhen termin. ZAKLUChOTsIRizik analizata od koja proizleguva planot za proverkapretstavuva odlichen sistem za kompletno sledenje na statusot nais porachatelite so shto mnogu lesno se izdvojuvaat i priore ti za -ra at proverkite na visoko rizichnite i regulatorno potrebniteisporachateli. Proverkata na isporachatelite na vlezni materijali pretstavuvaalatka za evaluatsija na sistemot za kvalitet i proizvodnitekapatsiteti so koi tie raspolagaat i koja na kraj mozhe da rezultira soredutsirano testiranje [8]. Alkaloid AD ima jasna politika so kojaisporachatelite gi tretira kako partneri. Preku sistemot na redovniproverki, sekojdnevna komunikatsija i proverka na kvalitetot navleznite materijali Alkaloid AD e siguren vo kvalitetot na vleznitematerijali, istovremeno ispolnuvajkji gi regulatornite baranja koise odnesuvaat na isporachatelite na vlezni materijali.LITERATURA1. Protsedura za Otsenka na isporachateli A 2 7.4. 02 ver. 2 2. McKilligan R G., MHRA GMP Inspector: API Focussed MHRA Inspections atDosage Form Manufacturers, 2010 3. Directive 2001/83/EC/ 46f of the European parliament and of the council from 06.11.2001249Macedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL TECHNOLOGY AND BIOPHARMACYposter presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATION4. EudraLex, Volume 4 Good manufacturing practice (GMP) Guidelines, Part I5. EudraLex, Volume 4 Good manufacturing practice (GMP) Guidelines, Part II, 5.406. EU GMP Annex 8- Sampling of starting and packaging materials 7. ICH Q9 Quality risk management adopdet by the European medicenes agency on31.01.20118. EudraLex, Volume 4 Good manufacturing practice (GMP) Guidelines, Part I, DraftversionmChapter 5STERILE MULTIDOSE LIDOCAINE 2 %ANESTETIC GEL - GALENIC PREPARATIONAS A REPLACEMENT OF THE COMMERCIALPRODUCT T. Dimitrovska Manojlovikj1, M. Pavlovska2.1Clinical hospital-Bitola, Hospital pharmacy-pharmacoinformativecentre, Bitola, R. Macedonia2Clinical hospital-Bitola, Hospital pharmacy, Bitola, R. MacedoniaINTRODUCTIONFacing the problem of deficiency of a commercial pharmaceuticaldosage form of Lidocaine 2% anesthetic gel from the pharmaceuticalindustry in our country we have decided to prepare it as a galenicpreparation and research its microbiological and content integrity. Infact, in the moment of our decision there was a deficiency ofregistered commercial pharmaceutical dosage form of that productthat is extently applied in the most of the hospital wards. So, providingthe hospital wards with this preparation was our initiative that obligedus to solve this problem.OBJECTIVESTo supply hospital wards with lidocaine 2% anesthetic gel withcompounded galenic preparation - Sterile multidose 2% Lidocaine gelas a replacement of the industrial commercial preparation.METHODSAfter extensive research of the terciary and primary literature throughvarious and on line compendium formulations we developed our owncomposition according to our ingredients and hospital wards needs.Ingredients used for this preparation were: powder Lidocaine HCl(Sigma-Aldrich,USA,USP), Carboxymethyl-cellulose Na, high viscosity(Sigma-Aldrich,USA,USP), Aqua sterillisata 3rd Ed, PhP, 1998 (ourhospital Department for infusion solutions production. ).We preparedthe gell in the galenic laboratory in the pharmacy. Then we sterilisedextemporaneously prepared gel according Ph.Eu. 3rdEd. PhP, 1998,with autoclave sterilisation process in the Department for infusionsolutions production in our hospital) and in the same department wepacked it according Ph.Eu.3rdEd, with aseptic procedure in the 10 mlsterile syringes (BD and Co. Discardit TM, NJ,USA). Tests of the contentof lidocaine HCl in this preparation were performed in the Analyticallaboratory at the Department for infusion solutions production in ourhospital. Sterility tests were performed in the Microbiologycaldepartment of Centre for public health, Bitola. RESULTSContent analysis of lidocaine HCl confirmed that the preparation metthe requirements (average content =19.90 mg lidocaine HCl/1 g gel).Average pH = 6.7 and meets the requirements too. Sterility controltests also confirmed the sterility or consent of the preparation withthe pharmacopoeial requrements. DISCUSSION AND CONCLUSIONWe formulated our own formulation and producing process for sterilemultidose anesthetic Lidocaine 2% gel. Primarly we prepared a smallamount i.e. small series of the preparation, on wich all tests weperformed respectively. On the base of results we produced largequantity and packed it as a multidose preparation. The wholeprocedure of preparing of this preparation was: 1.developing suitableformulation; 2.compunding/producing of the gel; 3.sterilising of thegel with autoclaving; 4.packing; 5.content test of the active substance;6. pH determination; 7.sterility control test.Taking all these into consideration, we prepared sterile multidoselidocaine 2% anesthetic gel in the hospital pharmacy of the Clinicalhospital in Bitola and we surpass the problem of deficiency in ourcountry of the commercial pharmaceutical dosage form for supplayingof the hospital wards.LITERATURE1. Martindale The complete drug reference, 34th Ed. PhP, London, Chicago, 20052. Remington's Pharmaceutical Sciences, 17th Edition. Mack Publishing Co., Easton, PA, 19853. www. Compounding Today. com4. USP 31, The United States Pharmacopeial Convevtion 12601 Twinbrook Parkway, Rockville, MD 20852, may 20085. Ph. Eu. 3rd Ed, PhP, 1998 6. Pharmaceutical Dosage Forms and Drug Delivery Systems by Howard C. Ansel, Lippincott Williams & Wilkins, oct. 19997. Merck Index, 12th Edition, 1996 for solubility information 8. Handbook of Pharmaceutical Excipients, 4th edition, 20039. http//pharmlabs.unc.edu, then select Suspensions and GelsSTERILEN POVEKjEDOZEN LIDOKAIN 2% GEL - GALENSKIPREPARAT KAKO ZAMENA NA GOTOV LEKT. Dimitrovska Manojlovikj1, M. Pavlovska2.1Klinichka bolnitsa - Bitola, Bolnichka apteka,Farmakoinformativen tsentar, Bitola, R. Makedonija2Klinichka bolnitsa - Bitola, Bolnichka apteka, Bitola, R. MakedonijaVOVEDSoochuvajkji se so problemot na nedostatok na gotova farmatsevtskadozirana forma - Lidokain 2% anestetichen gel odfarmatsevtstkata industrija vo nashata zemja, nie odluchivme dapripremime galenski preparat i da ja ispitame negovatamikrobioloshka stabilnost i soodvetnost na sodrzhinata naaktivnata komponenta. Vo momentot na nashata odluka postoeshedefitsit na registrirana gotova farmatsevtska dozirana formana ovoj prpeparat, koj nashiroko se upotrebuva vo bolnichkiteoddelenija. Zatoa, snabduvanjeto na bolnichkite oddelenija so ovojpreparat beshe nasha initsijativa shto ne obvrza da go reshimeproblemot.Tsel na trudot: Snabduvanje na bolnichkite oddelenija so Lidokain250Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA TEKhNOLOGIJA I BIOFARMATsIJAposter prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVO2% anestetichen gel so galenski pripremen preparat - Sterilenpovekjedozen lidokain 2% gel kako zamena za fabrichki gotov lek.METODIPosle shiroko prebaruvanje na tertsierna i primarna literaturaniz razlichni formulatsii i "on line" kompendiumi, nie razvivmenasha sopstvena formulatsija vodejkji se od nashite raspolozhlivisostojki i potrebite na bolnichkite oddelenija. Sostojkiteupotrebeni za ovoj preparat se: prashok Lidocaine HCl (Sigma-Aldrich,USA,USP), prashok Carboxymethyl-cellulose Na, high viscosity(Sigma-Aldrich,USA,USP), Aqua sterillisata, Ph.Eur. 3rd Ed, PhP, 1998(proizvod na Oddelenieto za infuzioni rastvori vo nashatabolnitsa). Nie go pripremivme gelot vo galenskata laboratorija vobolnichkata apteka. Potoa go steriliziravme taka pripremeniotgel vo soglasnost so baranjata na Ph.Eu. 3rdEd. PhP, 1998, soterminalna sterilizatsija - avtoklaviranje vo Oddelenieto zainfuzioni rastvori vo nashata bolnitsa. Vo istoto oddelenie gelotgo spakuvavme vo soglasnost so baranjata na Ph.Eur. 3rd Ed, PhP, 1998,so aseptichna postapka vo sterilni shpritsevi od 10 ml. (BD andCo. Discardit TM, NJ,USA). Testovite na sodrzhinata na lidokainkhidrokhlorid gi izvedovme vo oddelot za kontrola na lekovi priOddelenieto za infuzioni rastvori vo nashata bolnitsa, atestovite na sterilnost bea izvedeni vo mikrobioloshkatalaboratorija na Tsentarot za javno zdravje vo Bitola. REZULTATIAnalizata na sodrzhinata na lidokain khidrokhlorid potvrdi dekapreparatot gi zadovoluva baranjata (sredna vrednost e 19.90 mg.Lidokain khidrokhlorid na 1 g. gel). Sredna rN vrednost e 6.7 i istotaka gi zadovoluva baranjata. Testovite za kontrola na sterilnostaisto taka ja potvrdija sterilnosta na preparatot, soodvetno nafarmakopejskite baranja. DISKUSIJA I ZAKLUChOTsIFormuliravme nasha sopstvena formulatsija i proizvodnapostapka za sterilen povekjedozen anestetichen Lidokin 2% gel.Najprvo pripremivme mala kolichina, odnosno mali serii napreparatot, na koi soodvetno gi napravivme site testovi. Vrzosnova na dobienite rezultati napravivme golema kolichina i jaspakuvavme kako povekjedozen preparat. Tselosnata postapka napripremanje na ovoj preparat opfakja: 1. razvivanje na soodvetnaformulatsija; 2. izrabotka na gelot; 3. terminalna sterilizatsija -avtoklaviranje; 4. pakuvanje; 5. ispituvanje na sodrzhina na aktiv na -ta komponenta; 6. odreduvanje na rN vrednost; 7. test na sterilnost.Zemajkji go seto ova vo predvid, nie pripremivme sterilenpovekjedozen lidokain 2% anestetichen gel vo bolnichkata apteka naKlinichka bolnitsa - Bitola i go reshivme problemot na defitsit na go -tov fabrichki lek za snabduvanje na oddelenijata vo nashata bolnitsa. LITERATURA:1. Martindale The complete drug reference, 34th Ed. PhP, London, Chicago, 20052. Remington's Pharmaceutical Sciences, 17th Edition. Mack Publishing Co., Easton, PA, 19853. www. Compounding Today. com4. USP 31, The United States Pharmacopeial Convevtion 12601 Twinbrook Parkway, Rockville, MD 20852, may 20085. Ph. Eu. 3rd Ed, PhP, 1998 6. Pharmaceutical Dosage Forms and Drug Delivery Systems by Howard C. Ansel, Lippincott Williams & Wilkins, oct. 19997. Merck Index, 12th Edition, 1996 for solubility information 8. Handbook of Pharmaceutical Excipients, 4th edition, 20039. http//pharmlabs.unc.edu, then select Suspensions and GelsGMP IN THE PRODUCTION OF INFUNDIBILIAM. PavlovskaKlinicka bolnica Bitola, Bolnicka apteka Bitola, R. MakedonijaINTRODUCTIONThe validation of the process of sterile production can not be donebefore the previous implementation of Qualification of procedures,Qualification of Equipment, Facility, Systems, and Process validationwhich are different segments of the process of sterile productionwhere we have terminal sterilization. PURPOSETo demonstrate the validation of the process of sterile production ofinfundibilija of Natrii chloride infundibile cum glucose 5%,0,9% (2:1)through the research of three consecutive pilot series.